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The intake of probiotics has been associated with
beneficial effects on the immune system, such as im-
proved disease resistance and diminished risk of al-
lergies. This review gives an overview of the immu-
nomodulatory effects of probiotics investigated with in
vitro assays, experimental animal models, and clinical
trials, and explores possible mechanisms underlying
the immunomodulatory effects. Immunomodulation,
however, is not always beneficial and might induce
detrimental effects; therefore, a scheme is proposed
for benefit-risk assessment of immunomodulation by
probiotics. Within this scheme, expert judgment based
on data derived from a panel of in vitro assays, animal
models, and clinical trials should lead to conclusions
on efficacy and safety aspects of probiotics.
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INTRODUCTION
Probiotics are dietary supplements that are by defi-
nition “living microorganisms, which, upon ingestion in
sufficient numbers, exert health benefits.”1 The most
commonly used probiotics are lactic acid bacteria,
mainly Lactobacillus and Bifidobacterium strains. Health
effects that are ascribed to the intake of probiotics in-
clude beneficial effects on disease resistance,2-6 gastro-
intestinal diseases,7-9 and allergies.10-12 Mechanisms un-
derlying these beneficial effects are not completely
understood, so the effects of probiotics should not be
generalized, because different strains can exert different
effects.
This review gives an overview of immunomodula-
tion by probiotics in experimental animal models of
allergy, autoimmunity, and inflammatory bowel disease
(IBD), and presents available data on probiotic effects
and the mechanisms involved as assessed in clinical
trials. Modulation of the immune system might improve
allergic, autoimmune, or inflammatory disorders, but
may have undesired effects under certain circumstances.
There are currently no guidelines to evaluate the
efficacy and safety of probiotics; therefore, an approach
for efficacy and safety evaluation of probiotics will be
proposed in this review. This approach is based on
guidelines previously proposed by others, but is extended
with respect to immunomodulatory effects and provides
a decision scheme that can be used to evaluate newly
marketed probiotic products. In this decision scheme,
expert judgment is used to determine if health claims are
plausible and adverse effects are possible.
PROBIOTICS AND ALLERGIC DISEASES
Several reports have shown that probiotic bacteria
skew the Th1/Th2 balance toward Th1, which may
beneficially down-regulate overactive Th2-mediated al-
lergic responses. Stimulation of Th1 immunity has been
confirmed in in vitro studies showing increased produc-
tion of Th1 cytokines (IL-12, IL-18, and IFN-) in
human monocytes and peripheral blood mononuclear
cells (PBMCs) after incubation with several lactoba-
cilli.13,14 Additionally, effects on the Th1/Th2 balance
have been observed in animal models of allergy. In
BALB/c mice sensitized with ovalbumin and orally
treated with Lactobacillus casei Shirota, splenocytes
stimulated with ovalbumin ex vivo produced more Th1
cytokines (IFN-) and fewer Th2 cytokines (IL-4, IL-5,
IL-6, and IL-10). Furthermore, the production of total
and ovalbumin-specific IgE levels were suppressed. In a
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murine food allergy model, Lactobacillus plantarum in-
creased plasma IL-12 levels and suppressed allergen-
specific IgE levels, and this effect was IL-12 depen-
dent.15 However, not all probiotic strains stimulated Th1
immunity. Lactobacillus rhamnosus HN001, for in-
stance, stimulated a mixed Th1/Th2 cytokine pattern in a
murine model of respiratory allergy.16 Thus, L. rhamno-
sus HN001 acted more as a general stimulator of the
immune response, and therefore this probiotic might not
be suitable for general use, but could possibly be used as
an adjuvant.
Stimulation of Th1 immunity has been observed in
clinical trials (Table 1). The effects of L. rhamnosus GG
or a mixture containing L. rhamnosus GG, L. rhamnosus
LC7055, Bifidobacterium breve Bbi99, and Propionibac-
terium freudenreichii ssp. shermanii on infants with
cow’s milk allergy and IgE-associated dermatitis was
investigated in a double-blind, placebo-controlled
study.17 Intake of L. rhamnosus GG for 4 weeks allevi-
ated skin symptoms, whereas the mixture did not affect
clinical symptoms. This differential effect might be ex-
plained by differences in cytokine profiles measured
after PBMC stimulation. IFN- secretion was signifi-
cantly increased after L. rhamnosus GG intervention. In
contrast, the mixture of probiotics did not affect IFN-
secretion, but did increase the amount of IL-4. Appar-
ently, the other probiotic strains present in the mixture
stimulated a Th2 response that inhibited L. rhamnosus
GG-induced Th1 responses. Furthermore, cytokine pro-
files appear to predict the effects on clinical symptoms.17
Several other studies report effects of probiotics on
atopic eczema. In a randomized, double-blind, placebo-
controlled study, 27 infants with atopic eczema received
Bifidobacterium lactis Bb12, L. rhamnosus GG, or for-
mula without probiotics for 2 months. Consumption of B.
lactis Bb12 and L. rhamnosus GG decreased signifi-
cantly the SCORAD (SCORing Atopic Dermatitis) score
in all infants, reflecting an improvement in skin condi-
tion. In the control group, SCORAD decreased in 4 out
of 9 infants. After 6 months, skin symptoms were absent
in all groups. The intake of probiotics affected several
immune parameters, such as decreased serum-soluble
CD4, a marker for T-cell activation, in both probiotic
groups, whereas serum TGF- decreased in infants re-
ceiving B. lactis Bb12 and slightly but not significantly
increased in the L. rhamnosus GG group. Also, eosino-
philic protein X, a urine marker for eosinophilic inflam-
matory activity, was reduced in both probiotic-supple-
mented groups.18
Beneficial effects of L. rhamnosus GG consumption
on atopic eczema have been confirmed in another dou-
ble-blind, randomized, placebo-controlled trial. L. rham-
nosus GG (n  68) or placebo (n  64) was given
prenatally to mothers with a family history of atopic
disease. After delivery, breast-feeding mothers continued
intake of L. rhamnosus GG and infants that were not
breast-fed received L. rhamnosus GG for 6 months. Both
treatments resulted in similar amounts of L. rhamnosus
GG in infant feces. After 2 years, the percentage of
infants diagnosed with atopic eczema was significantly
reduced in the L. rhamnosus GG group (23%) compared
with the placebo group (46%). However, surprisingly,
probiotic intervention did not affect total IgE levels or
the percentage of children with a positive skin-prick test,
indicating that L. rhamnosus GG did not influence the
allergic response.19 This cohort was re-examined at the
age of 4 years. Although fewer children in the probiotic
group were diagnosed with atopic eczema (14/53 com-
pared with 25/54 in the placebo group), there was also a
non-significant trend toward increased rates of other
atopic disorders (allergic rhinitis and asthma) in this
group.20
Another double-blind, placebo-controlled, crossover
study investigated the effects of L. rhamnosus 19070-2
and Lactobacillus reuteri DSM 122460 on atopic ec-
zema. Both probiotics were given in combination for 6
weeks to 1- to 13-year-old children (n 43) with allergic
and non-allergic eczema. After treatment, 56% of the
children who received probiotics experienced improve-
ment of eczema, whereas only 15% showed improved
symptoms in the placebo group. The effects of probiotics
seem to be more pronounced in allergic patients, because
in allergic infants SCORAD decreased, whereas it was
not affected in the total group.21
In the same cohort of patients, Rosenfeldt et al.22
found a positive association between impairment of in-
testinal permeability and severity of eczema. The intake
of probiotics significantly decreased gastrointestinal
symptoms and diminished intestinal permeability. An-
other study reported that infants with cow’s milk allergy
and atopic eczema suffered from intestinal inflammation,
as demonstrated by increased fecal TNF-. After 1
month of intervention with L. rhamnosus GG (n  15),
SCORAD scores had improved significantly and fecal
TNF- was reduced. Notably, in the placebo group the
SCORAD and fecal TNF- were reduced after 2
months.23 Thus, beneficial effects of probiotics might be
explained by the stabilizing effects of probiotics on
intestinal microflora and barrier function. In addition, the
beneficial effects of probiotics might be explained by
their influence on immunoregulatory mechanisms, be-
cause improvement of atopic dermatitis after consump-
tion of L. rhamnosus GG for 4 weeks has been shown to
be associated with elevated levels of serum IL-10,24 an
anti-inflammatory cytokine that inhibits synthesis of sev-
eral cytokines and down-regulates IgE synthesis. Thus,
probiotics seem to improve atopic eczema via different
mechanisms, which are listed in Table 2.
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The hypothesized beneficial effects of probiotics on
allergic disorders such as asthma or food allergy have not
been convincingly demonstrated in clinical trials. In a
crossover study, 20 patients with allergic rhinitis con-
sumed either yogurt containing Lactobacillus bulgaricus
and Streptococcus thermophilus or milk without probi-
otics for 1 month. After a washout period of 2 weeks,
individuals who received yogurt with probiotics in the
first period received milk for 1 month and vice versa.
Several immune parameters were assessed: blood count
and differentiation; serum IgG, IgA, IgM, and IgE;
mitogen-induced proliferation and cytokine production;
neutrophil chemotaxis and oxidative burst; phenotyping
of blood cells with flow cytometry; and natural killer cell
(NK) function. The consumption of yogurt slightly in-
creased lymphocyte IL-2 production (P  0.09), but
other immune parameters were not affected.25 A similar
crossover design was applied to study the effects of
yogurt containing Lactobacillus acidophilus, L. bulgari-
cus, and S. thermophilus or the same yogurt without L.
acidophilus in 15 atopic patients with asthma and/or
rhinitis. There were no statistical differences observed
pre- or post-treatment, but IFN- production by PBMCs
stimulated with concavalin A was slightly enhanced and
blood eosinophilia were somewhat decreased. Serum IgE
levels and clinical parameters such as pulmonary func-
tion and quality of life were not affected.26 Thus, al-
though some immune parameters seem to be slightly
modulated by the intake of probiotics, asthmatic symp-
toms do not improve.
In another study,27 patients with rhinitis received
yogurt supplemented with Lactobacillus delbruekki, L.
bulgaricus, S. thermophilus, L. acidophilus, and Bi-
fidobacterium (n 7) or skim milk (n 6) for 4 months.
After intervention with probiotics, cytokine levels were
modulated, but this effect was not significant. IFN-
levels were increased in unstimulated PBMCs and IL-4
levels were decreased in phytohemagglutinin-stimulated
PBMCs. Furthermore, there were no effects on skin-
prick tests and serum IgE. Remarkably, the subjective
sensation of well-being was higher in patients who con-
sumed yogurt with probiotics than in controls.27 In ad-
dition, in patients with birch-pollen allergy (n  18 per
group), the consumption of L. rhamnosus or placebo for
5.5 months starting 2 months before the pollen season
did not alleviate symptoms or reduce the use of medica-
tion.28
From the studies described above, it can be con-
cluded that probiotics seem to accelerate improvement of
atopic eczema, and L. rhamnosus GG in particular ap-
pears to be effective. However, effects on other allergies
are not very convincing, and the exact mechanisms are
unclear. To obtain more insight into the complexity of
probiotic effects on allergic diseases, mechanisms should
be elucidated with experimental animal models and clin-
ical trials should be performed with sufficient individuals
per group to establish efficacy.
SUPPLEMENTATION OF BABY FORMULAS
WITH PROBIOTICS
There are now baby formulas on the market that
have been supplemented with probiotics (one, for exam-
ple, contains B. lactis Bb12 and S. thermophilus Th4).
The rationale for such a use is the observed association
between microflora and allergies. Microflora of children
from Estonia, a country with a low prevalence of aller-
gies, contains higher numbers of lactobacilli compared
with children from Sweden, a country with a high prev-
alence of allergies.29 In addition, allergic infants in both
countries were less often colonized with lactobacilli and
bifidobacteria than non-allergic children.30
A prospective study31 investigated the intestinal mi-
croflora of 76 infants with a predisposition to develop
atopic diseases. At the age of 12 months, 29% of these
children had a positive skin-prick test. Remarkably, at
the age of 3 weeks, these allergic infants had a lower
ratio of bifidobacteria to clostridia compared with non-
allergic infants. Dietary characteristics between atopic
and non-atopic infants were similar. At the age of 3
weeks, 73% of the atopic and 68% of the non-atopic
infants were exclusively breast-fed, 27% of the atopic
and 28% of the non-atopic infants were breast-fed and
formula-fed, and 4% of the non-atopic infants were
formula-fed. At the age of 3 months, the dietary charac-
teristics changed but were similar when comparing
atopic (50% breast-fed, 27% breast-fed and formula-fed,
and 23% formula-fed) and non-atopic (54% breast-fed,
Table 2. Mechanisms by Which Probiotics Can Affect Atopic Eczema
Mechanism Probiotic Reference
Immune effects: decreased serum-soluble CD4 (a T-cell marker)
and increased TGF- after Bifidobacterium lactis Bbl2
B. lactis Bb12 or
Lactobacillus
rhamnosus GG
Isolauri et al., 200018
Effect on Th1 immunity (increased IFN-) L. rhamnosus GG Pohjavuori et al., 200417
Immunoregulation (increased IL-10) L. rhamnosus GG Pessi et al., 200024
Effects on intestinal permeability L. rhamnosus GG Rosenfeldt et al., 200422
Alleviation of intestinal inflammation L. rhamnosus GG Majamaa et al., 199723
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26% breast-fed and formula-fed, and 20% formula-fed)
subjects. The results of this study might indicate that
differences in microflora early in life precede the devel-
opment of atopy.31 It has also been shown that the
microflora of formula-fed infants is more complex than
that of breast-fed infants, and contains a complex mix-
ture of anaerobic strains such as Bacteroides and Clos-
tridium, while breast-fed infants are colonized with pre-
dominantly bifidobacteria and lactobacilli.19 Thus,
supplementation of baby formulas with probiotics may
modulate the microflora of infants and help to prevent
allergies.
However, although probiotics have a long history of
safe use, it is unknown if consumption early in life can
induce adverse long-term effects. In a prospective, dou-
ble-blind, randomized, placebo-controlled study, healthy
infants age 3 to 24 months received a baby formula with
B. lactis and S. thermophilus for a period of 210 (127)
days. Probiotics were well-tolerated by these infants
without any influence on growth, formula intake, epi-
sodes of fever or diarrhea, or day care attendance. Fur-
thermore, probiotics were associated with a significantly
lower frequency of reported colic, irritability, and anti-
biotic use.32 The probiotic infant formulas currently on
the market come with instructions that their use should
be restricted to infants older than 4 months who are not
immunocompromised.33
The effects of probiotic consumption immediately
after birth, when the human gut is sterile and probiotics
probably can colonize the host, are unknown. Experi-
ments in congenitally immunodeficient, gnotobiotic,
athymic mice have shown that L. acidophilus, L. reuteri,
Bifidobacterium animalis, and L. rhamnosus GG are able
to colonize and persist in the gastrointestinal tract. This
was observed not only in adults, but also in offspring
born from probiotic-exposed mothers. Infants were not
given probiotics, but were exposed to them from feces
and feed. More importantly, L. rhamnosus GG and L.
reuteri caused some mortality in athymic neonates (36%
and 21%, respectively), a phenomenon that did not occur
in adults.34 Thus, probiotics might not be safe in immu-
nodeficient neonates, and their prophylactic use to pre-
vent allergies cannot be recommended, because both
efficacy and safety issues are not convincingly demon-
strated yet. As suggested previously,35 more information
from well-designed clinical trials assessing the effects of
probiotics on allergies is needed to make a proper deci-
sion on the pros and cons of probiotic use in infants.
PROBIOTICS AND AUTOIMMUNITY
Although most studies focus on the effects of
probiotics on allergies, there have also been studies
investigating their effects on autoimmunity. Stimula-
tion of Th1 immunity by probiotics would not be
desirable in autoimmunity, because enhanced Th1 re-
sponsiveness may aggravate Th1-mediated autoim-
mune diseases. Data obtained in experimental animal
models suggest that probiotics can modulate the im-
mune system via other mechanisms. The effects of L.
casei Shirota have been studied in two experimental
models of insulin-dependent diabetes mellitus: allox-
an-induced diabetes and non-obese diabetic (NOD)
mice.
36, 37
In both models, L. casei Shirota decreased
the incidence of diabetes, slightly reduced plasma
glucose levels, and prevented the destruction of the
-cells and islets of Langerhans. In the alloxan model,
destruction of -cells was caused by nitric oxide.
After probiotic administration, plasma nitric oxide
levels were reduced via an unexplained mechanism.36
The effects of L. casei Shirota in NOD mice might be
explained by the observed shift in Th1/Th2 balance to
Th2. Spleen cells stimulated with concavalin A pro-
duced less IFN- and more IL-2, IL-4, IL-6, and
IL-10. Furthermore, after L. casei Shirota treatment,
the number of CD8 T-cells, which are involved in the
destruction of -cells, was lower.37
L. casei Shirota seemed to stimulate Th1 responses
in this experimental diabetes model,37 while in an exper-
imental allergy model, L. casei Shirota decreased Th1
responses.38 This suggests that the immunomodulatory
effects of probiotics cannot simply be explained by
skewing of the Th1/Th2 balance to Th1. Supposedly,
immunomodulation is regulated at another level. In vitro
experiments have shown that Lactobacillus paracasei
NCC2461 inhibited T-cell proliferation via induction of
a regulatory cytokine profile with enhanced levels of
IL-10 and TGF- and decreased levels of both Th1 and
Th2 cytokines.39 L. casei Shirota may have affected both
autoimmunity and allergy via immunoregulatory mech-
anisms.
Immunoregulation induced by probiotics could be
involved in experimental murine models of rheumatoid
arthritis.
40, 41
Lactobacillus salivarius 118 reduced disease
severity in collagen-induced arthritis. Furthermore, this
probiotic strain reduced IL-12 and TNF- and increased
TGF- in mice with experimental colitis.40 Improvement
of arthritis might be caused by down-regulation of IL-12
and TNF-, cytokines that play a critical role in colla-
gen-induced arthritis.42 L. casei Shirota reduced anti-
collagen-specific immunoglobulin levels and specific
delayed-type hypersensitivity (DTH) responses. Further-
more, L. casei Shirota reduced Th1 responses but not
Th2 responses, again illustrating that that probiotics do
not always stimulate Th1 responses.41 In tropomyosin
arthritis or adjuvant arthritis in rats, intervention with L.
rhamnosus GG reduced inflammation but did not affect
anti-tropomyosin antibody titers.43
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It has been suggested that there is an association
between intestinal microflora and rheumatoid arthritis.
Microflora from patients with newly developed rheuma-
toid arthritis have a significantly different bacterial flora
in their feces compared with controls.44 This may sug-
gest that probiotics affect experimental arthritis by influ-
encing intestinal microflora; however, this has not been
seen in experimental models of arthritis. Information on
the effects of probiotics in patients with rheumatoid
arthritis is also scarce, due to a lack of clinical trials
investigating the effects of probiotics. In one placebo-
controlled trial, patients were randomized to receive L.
rhamnosus GG (n  8) or placebo (n  13) for 12
months. Intervention with L. rhamnosus GG did not
improve clinical symptoms or anti- and pro-inflamma-
tory cytokines in serum. However, probiotic intake
seemed to reduce the occurrence of swollen joints, al-
though this effect was not significant.45
Clearly, more clinical trials are needed to confirm
the effects of probiotics on immunity that have been
observed in experimental arthritis models. Experimental
data obtained in a murine model for multiple sclerosis
(experimental autoimmune encephalomyelitis) demon-
strated that different probiotic strains induced opposing
effects. The probiotic L. reuteri aggravated the disease,
whereas L. casei and Lactobacillus murines ameliorated
it. Cytokine profiles induced by the different strains seem
to predict clinical outcome. L. reuteri induced a Th1-like
profile (TNF- and IL-2) in the gut and adjuvated the
immune response to a parenterally administered antigen.
In contrast, L. casei induced immunoregulatory cyto-
kines (TGF- and IL-10) in the gut and did not show any
adjuvant activity.46 These findings suggest that probiot-
ics with intrinsic adjuvant activity can have detrimental
effects on autoimmune diseases, and that cytokine pro-
files might be useful for proper strain selection.
EFFECTS OF PROBIOTICS ON
INFLAMMATORY BOWEL DISEASE
More mechanistic information has been obtained in
experiments studying the effects of probiotics on IBD
(Crohn’s disease and ulcerative colitis). In IBD, toler-
ance of the mucosal immune system against the intestinal
microflora appears to be lost, and this is thought to
contribute to intestinal inflammation.47 Probiotics have
been shown to be beneficial in several animal models of
IBD. For example, the administration of L. reuteri in a
rat model of acetic acid-induced colitis improved gut
permeability and reduced intestinal inflammation.48
Also, L. plantarum DSM 9843, Bifidobacterium sp. 3B1,
and Bifidobacterium infantis DSM 15158 were all able to
significantly improve the clinical score in dextran sulfate
sodium-induced colitis.49 In contrast, L. plantarum could
not reduce the severity of colitis nor improve gut perme-
ability in trinitrobenzene sulfonic acid-induced colitis.50
In humans, effects of the probiotic Escherichia coli
Nissle 1917 on ulcerative colitis have been studied in a
randomized, double-blind trial. Patients were random-
ized to treatment with either a probiotic (n  110) or
mesalazine (n  112), the drug that is normally pre-
scribed to treat colitis, for 12 months. Relapses were
similar in patients treated with E. coli Nissle 1917 (37%)
and mesalazine (34%), and E. coli Nissle 1917 appeared
to be equivalent to mesalazine in maintaining remis-
sion.51 In a comparable study design, 57 active colitis
patients were treated with E. coli Nissle 1917 and 59
with mesalazine for 12 months. A total of 44 mesazaline-
treated patients and 39 patients receiving E. coli Nissle
1917 went into remission and could be followed for
relapse. Again, E. coli Nissle 1917 was as effective as
mesalazine in maintaining remission.52
In a randomized, placebo-controlled trial, effects of
the probiotic cocktail VSL#3, containing L. casei, L.
plantarum, L. acidophilus, Lactobacillus delbrueckii bul-
garicus, B. breve, B. longum, B. infantis, and Strepto-
coccus salivarius thermophilus, on remissive pouchitis
were investigated. Patients received either VSL#3 (n 
20) or placebo (n  16) for 12 months, and remission
was maintained in 85% of the patients who received the
VSL#3 cocktail and in 6% of those who received the
placebo. Thus, the VSL#3 cocktail effectively main-
tained remission.53
In another randomized, placebo-controlled trial, the
effects of L. rhamnosus GG on Crohn’s disease were
investigated. Only those patients who had had all of the
inflamed gut removed surgically were included. Patients
were randomized to receive either L. rhamnosus GG
(n  23) or placebo (n  22). However, the intake of
probiotics did not prevent endoscopic recurrence of the
disease.54 Thus, not all probiotic strains seem to be
equally effective in treating IBD. Furthermore, Crohn’s
disease and colitis do not have the same etiology, and
this might explain the different effects. Table 3 summa-
rizes the effects of probiotics on IBD.
INVOLVEMENT OF TOLL-LIKE RECEPTORS
AND IMMUNOREGULATION
Exact mechanisms underlying the beneficial effects
of probiotics are not completely understood, but might
involve pattern recognition molecules such as toll-like
receptors (TLRs), which recognize pathogens by their
evolutionarily conserved microbial components.55 TLRs
are essential in innate defense against pathogens, and
trigger adaptive immune responses.56 Several studies
suggest that TLRs might be involved in the beneficial
effects elicited by probiotics. For example, E. coli Nissle
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1917 significantly reduced the capacity of peripheral
blood T-cells to proliferate following antigen stimula-
tion; inhibited the production of IL-2, TNF-, and
IFN-; and enhanced IL-10 production. The effects of E.
coli Nissle 1917 seem to be mediated by TLR2, because
no suppression was observed in T-cells from TLR2-
deficient mice.57 Aberrant T-cell responses seem to play
an important role in the loss of tolerance against intesti-
nal microflora, and the suppressive effects of probiotics
on T-cells mediated via TLR signaling might therefore
reduce intestinal inflammation. The involvement of
TLRs in the improvement of colitis was observed in
dextran sulfate sodium-induced colitis. The probiotic
cocktail VSL#3 improved colitis in wild-type mice but
not in TLR9-deficient mice.58
Regulatory cytokines also seem to be involved in the
beneficial effects of probiotics on colitis. The VSL#3
cocktail administered for 3 weeks to mice after recovery
from initial induction of trinitrobenzene sulfonic acid-
induced colitis and before second induction of (recur-
rent) trinitrobenzene sulfonic acid-induced colitis re-
sulted in a milder form of colitis, which was attributed to
elevated IL-10 production and increased regulatory
CD4 T-cells.59
It is unknown what triggers the activation of regu-
latory T-cells after probiotic administration, but dendritic
cells might be involved. Dendritic cells are abundantly
present in the gastrointestinal tract and are the principal
stimulators of naive T-cells. As such, they play a crucial
role in the polarization of the immune response to Th1,
Th2, and regulatory T-cell responses.60 In vitro studies
have shown that probiotics affect dendritic cell matura-
tion and cytokine secretion, although different and op-
posing effects were observed (e.g., production of Th1
cytokines, immunoregulatory cytokines, or both). These
differences might be explained by differences in Lacto-
bacillus strains, in the source of dendritic cells (human or
murine), or in culture conditions and exposure time. For
example, incubation of mouse bone marrow-derived den-
dritic cells with probiotic strains showed that all strains
induced IL-12, IL-6, TNF-, and IL-10 production, but
not all strains were equally effective. In addition, all
strains up-regulated maturation surface markers on den-
dritic cells (e.g., MHCII and CD86), but strains that
strongly induced IL-12 were the most effective.61 Mat-
uration of human peripheral blood-derived dendritic cells
was observed after incubation with Lactobacillus gas-
seri, Lactobacillus johnsonii, and L. reuteri, but these
strains only induced secretion of IL-12, not IL-10, and
skewed T-cell polarization toward Th1 and Tc1 cells.
Interestingly, all probiotic strains up-regulated TLR2
transcripts in dendritic cells, suggesting that TLR signal-
ing could be involved in dendritic cell maturation and
activation.62
The probiotic cocktail VSL#3 induced IL-10 pro-
duction in human intestinal lamina propria or blood-
derived dendritic cells and inhibited the generation of
Th1 cells. Interestingly, individual strains from the
VSL#3 cocktail displayed opposing effects. All strains
down-regulated IL-12 production, the bifidobacteria
stimulated IL-10, and all of the lactobacilli except L.
acidophilus down-regulated IL-10.63 Similarly, incuba-
tion of human monocyte-derived dendritic cells with L.
rhamnosus induced dendritic cell maturation to a more
regulatory profile, as judged by effects on T-cells. Prim-
ing T-cells with L. rhamnosus-matured dendritic cells
induced hyporesponsive T-cells that produced less IL-2,
IL-4, and IL-10 than T-cells primed with lipopolysac-
charide-matured dendritic cells. To confirm these in vitro
data, six patients with Crohn’s disease and six healthy
subjects received L. rhamnosus for 2 weeks. Ex vivo
stimulation of peripheral T-cells showed a similar hypo-
responsiveness after probiotic intervention, including de-
creased Th1 and Th2 responses without up-regulation of
immunoregulatory cytokines, in both healthy volunteers
and patients with Crohn’s disease.64
Probiotics seem to modulate the immune system via
several mechanisms, including TLR signaling and den-
dritic cell maturation, which can lead to stimulation of
Th1 responses, activation of regulatory T-cells, or induc-
tion of hyporesponsiveness. Therefore, probiotics and
probiotic effects cannot be generalized, and all strains
may not be suitable for common use. For example, the
induction of immunoregulation can be beneficial in both
allergic and autoimmune diseases, whereas probiotics
that have adjuvant properties or stimulate the Th1 re-
sponse might exacerbate autoimmune diseases. Further-
more, the induction of hyporesponsive T-cells might
impair immunity against infections, and is therefore not
suitable for use in the general population. For example,
L. rhamnosus GG induced different effects in healthy
volunteers and milk-hypersensitive subjects. In the latter,
L. rhamnosus GG intake prevented the increased expres-
sion of phagocytosis receptors, while in controls it ap-
peared to have an immunostimulatory effect, since re-
ceptor expression was increased. This suggests that
susceptibility for immunomodulation by probiotics is
different in healthy and hypersensitive subjects.65 Guide-
lines on how to evaluate probiotic strains clearly need to
be set.
ASSESSMENT OF EFFICACY AND SAFETY OF
PROBIOTICS
In the European Union, probiotics are regulated via
the Novel Food Regulation (258/97/EC). In short, this
regulation is only applied to strains that were not used
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before 1997 and concerns novel foods or food ingredi-
ents. The definition of novel foods is “foods and food
ingredients which have not hitherto been used for human
consumption to a significant degree within the commu-
nity.” To date, only in Denmark is it required that the
relevant authority be notified by the manufacturer prior
to the use of new probiotic strains. In France, a premarket
approval system for novel strains is being considered,
and proposed recommendations were published by
Agence Franc¸aise de Se´curite´ Sanitaire des Aliments.
In the United States, a probiotic used in food can be
classified as an additive, in which case it has to be
approved by the Food and Drug Administration (FDA)
on the basis of safety and efficacy data, or it can be
considered “generally recognized as safe” (GRAS). The
GRAS status is given to a probiotic when it has a history
of safe use in food dating before 1958 or has been
identified as safe by expert judgment under the condi-
tions of intended use.66,67
The approach proposed by the Food and Agriculture
Organization of the United Nations (FAO) and the World
Health Organization (WHO) may be useful in evaluating
newly discovered probiotics.68 According to this scheme
(Figure 1), the phenotype and genotype of probiotic
strains should first be established. Thereafter, assessment
of safety and efficacy and functional characterization of
probiotics should be performed with in vitro assays and
animal studies. In vitro assays can be used to gain
knowledge of probiotic strains and mechanisms of their
effects (e.g., adherence to epithelial cell lines or ability to
reduce pathogen adhesion to surfaces). If possible, in
vitro effects should be confirmed in animal models.
Then, probiotics have to be tested using standard meth-
ods in two clinical evaluations: phase 1 (safety assess-
ment) and phase 2 (efficacy assessment) studies. If these
clinical studies confirm efficacy and safety of a probiotic
strain, then that strain can be marketed as a probiotic
food. When a claim is made that a probiotic can alter a
disease state, then a phase 3 study must be performed.
This claim can only be made when it is based on sound
Figure 1. Food and Agriculture Organization of the United Nations (FAO) and World Health Organization (WHO) guidelines for the
evaluation of probiotics for food use. Available at: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.
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scientific evidence. Finally, the scheme provides recom-
mendations for labeling of probiotic foods.68
A similar approach has been proposed by Salminen
et al.69 (Figure 2), who recommends that the safety of
probiotics should be assessed in three steps. In the first,
the intrinsic properties of the strain (e.g., enzymatic
properties) should be studied. In the second, safety and
stability should be evaluated (e.g., survival in the gas-
trointestinal tract is a prerequisite for a probiotic strain,
but strains that can translocate and invade the host might
cause unwanted side effects). In the third step, interac-
tions between strain and host are studied. In this last step,
several functional and physiological aspects of probiotic
strains should be studied, either with in vitro assays or
animal models. For example, adherence to intestinal
epithelium can be studied with epithelial cell lines and
translocation can be studied in animal models. Ulti-
mately, clinical side effects should be studied in healthy
volunteers and patients.
In this approach, the stimulation and suppression of
immune responses is mentioned. Clearly, immunomodu-
lation should be investigated further, because several
studies have shown the immunomodulatory effects of
probiotics, and immunomodulation might induce un-
wanted effects on the host. Accordingly, in the efficacy
and safety assessment of probiotics, evaluation of the
immunomodulatory properties of a probiotic strain
should be included. Immunomodulatory effects of pro-
biotics vary with different types of bacteria and in dif-
ferent experimental models, so immunomodulation can-
not be assessed with one single assay, but requires a
panel of assays.
We propose a decision scheme based on another
scheme presented by Salminen et al.70 (Figure 3). To
assess immunomodulation, the effects of probiotics
should be studied with in vitro assays, experimental
animal models, and clinical trials. Initially, in vitro as-
says should be used to determine cytokine profiles.
Effects of probiotics should be studied in monocytes,
macrophages, or PBMCs, because it has been shown that
probiotics can induce the production of pro-inflamma-
tory cytokines in macrophages70 and Th1 cytokines in
peripheral blood monocytes.14 In addition, effects on
dendritic cell maturation and activation should be in-
Figure 2. Decision scheme for safety evaluation of probiotics (from Salminen et al., 199869).
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cluded, because probiotics can affect this maturation
differently,61,63 and this can influence the type of im-
mune response generated.60
Cytokine profiles may be predictive for the outcome
of immunomodulatory effects of a probiotic strain, but
additional information should be obtained from experi-
mental animal studies. Effects of probiotics should be
tested in several experimental disease models to establish
efficacy and possible unwanted effects. Preferably, pro-
biotics should be tested in host resistance models (cellu-
lar immunity), allergy models (Th2-mediated immune
responses), autoimmunity models, and contact hypersen-
sitivity models (the latter two are both Th1-mediated
immune responses). Ultimately, the probiotic strain
should be tested in clinical trials with the approach that
was proposed by the FAO/WHO (Figure 1) using stan-
dard phase 1 and 2 (and phase 3 if necessary) studies.68
Finally, all data available on a probiotic strain or probi-
otic product should be evaluated by an expert. Important
issues at this point are the plausibility of the health claim
and the possibility of adverse effects. Intended use
should also be taken into account.
The proposed approach is similar to the GRAS
notification procedure used in the United States in that it
is usually restricted to a specific application and not to
general use. For example, the FDA has accepted the use
of B. lactis Bb12 and S. thermophilus Th3 as ingredients
for an infant formula under the condition that it is
intended for consumption by infants 4 months and older
who are not immunocompromised.33 In the same man-
ner, the acceptance of probiotic products could only be
approved under certain restrictions such age and immune
status.
In the European Union, there is no special regulation
for supplementation of infant formulas with probiotics.
The Scientific Committee on Food of the European
Commission has recommended that infant formulas sup-
plemented with probiotics should only be marketed if
Figure 3. Proposal for a scheme that can be used for efficacy and safety evaluation of probiotics (adapted from Salminen et al., 199870).
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their benefit and safety have been evaluated according to
principles outlined by them.71 In addition, the European
Society for Paediatric Gastroenterology, Hepatology and
Nutrition Committee on Nutrition concluded that further
evaluation of the safety and efficacy of probiotic supple-
mentation of dietetic products for infants is necessary.
Concerns have been raised that available scientific data
are not sufficient to support the use of probiotics in
healthy newborn and very young infants with immature
defense systems.72 Finally, according to the scheme
presented in Figure 3, the surveillance of probiotic prod-
ucts on the market could provide more insight into both
efficacy and side effects after long-term consumption.
CONCLUDING REMARKS
Although the immunomodulatory effects of probiot-
ics have been demonstrated in experimental animal mod-
els of allergy, autoimmunity, and IBD, information from
clinical trials in humans is scarce. Furthermore, some
studies suggest that probiotics could induce detrimental
effects. Therefore, more research, especially in the form
of well-designed clinical trials, is needed to evaluate the
efficacy and safety of probiotics. The evaluation scheme
proposed here could provide a tool to standardize this
evaluation to obtain more insight into the complex nature
of the effects of probiotics.
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